Editorial overview - The T-helper1/T-helper2 paradigm: Still valid for drug discovery but with some essential refinement

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 487-488

  Korstanje, Cees ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT;

ATOPIC DERMATITIS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; EDITORIAL; HUMAN; IMMUNOLOGY; PSORIASIS; TH1 CELL; TH2 CELL;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PSORIASIS; TH1 CELLS; TH2 CELLS;

EID: 3342992560     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Garside P, Mowat AM: Polarization of Th-cell responses: A phylogenetic consequence of nonspecific immune defence? Immunol Today (1995) 16(5):220-222.
2. Romagnani S: The Th1/Th2 paradigm. Immunol Today (1997) 18(6):263-266.
3. Aleksza M, Lukacs A, Antal-Szalmas P, Hunyadi J, Szegedi A: Increased frequency of intracellular interleukin (IL)-13, and IL-10, but not IL-4, expressing CD4+ and CD8+ peripheral T cells of patients with atopic dermatitis. Br J Dermatol (2002) 147(6):1135-1141.
4. Novak N, Kruse S, Kraft S, Geiger E, Kluken H, Fimmers R, Deichmann KA, Bieber T: Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphism of the interleukin-4/interleukin-13 receptor gene: The dichotomy of extrinsic and intrinsic atopic dermatitis. J Invest Dermatol (2002) 119(4):870-875.
5. Gruber C, Illi S, Lau S, Nickel R, Forster J, Kamin W, Bauer CP, Wahn V, Wahn U: Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics (2003) 111(3):E282-E288.
6. Matsushima H, Hayashi S, Shimada S: Skin scratching switches immune responses from Th2 to Th1 type in epicutaneously immunized mice. J Dermatol Sci (2003) 32(3):223-230.
7. Herrick CA, Xu L, McKenzie AN, Tigelaar RE, Bottomly K: IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen. J Immunol (2003) 170(5):2488-2495.
8. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO: Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine (1999) 18(7-8):597-603.
9. Serebrisky D, Teper AA, Huang CK, Lee SY, Zhang TF, Schofield BH, Kattan M, Sampson HA, Li XM: CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol (2000) 165(10):5906-5912.
10. Jain VV, Kitagaki K, Kline JN: CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy (2003) 33(10):1330-1335.
11. Homey B: Interleukin-4: A new option in the therapy of systemic psoriasis? Hautarzt (2003) 54(10):1019-1020.
12. Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy - review of a new approach. Pharmacol Rev (2003) 55(2):241-269.
13. Röcken M, Racke M, Shevach EM: IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today (1996) 17(5):225-231.